A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Please provide your email address to receive an email when new articles are posted on . Patients who achieved undetectable measurable residual disease had a 72% reduced risk for disease progression or ...

Suchitra Sundaram, MD, reviews new data on CLL treatments presented at ASH 2024, highlighting exciting possibilities for future patient care. She recounts the case of a 75-year-old man with worsening ...

MRD quantification allows for improved PFS prediction in both patients who achive PR and CR, which thus supports its application in all responders. In contrast to residual lymphadenopathy, persisting ...

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of ...

Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma (PCNSL), stating the company ...